AbbVie’s Promising Pipeline: Fueling the Next Wave of Growth in Immunology, Oncology, and Beyond
AbbVie has successfully navigated the loss of exclusivity for its blockbuster Humira by building a powerful growth engine around Skyrizi (risankizumab) and Rinvoq (upadacitinib). Now, the company is doubling down on a deep and diversified pipeline designed to sustain momentum well into the next decade. With approximately 90 compounds, devices, or indications in development and around 60 programs in mid- to late-stage development, AbbVie continues to invest heavily in R&D—reporting $13.8 billion in 2025—while executing strategic acquisitions and advancing high-potential assets across immunology, oncology, neuroscience, eye care, and emerging areas like obesity.
Strengthening the Immunology Franchise
Immunology remains AbbVie’s core strength. The recent completion of its $10.9 billion acquisition of Apogee Therapeutics stands out as a major strategic move. The deal brings zumilokibart (formerly APG777), a half-life-extended anti-IL-13 monoclonal antibody, into the portfolio for moderate-to-severe atopic dermatitis. Phase 2 data showed roughly two-thirds of patients achieving significant skin clearance at week 16, alongside itch reduction and improved disease control. Longer-term results support convenient maintenance dosing—potentially quarterly or even twice yearly—positioning it as a differentiated option in a competitive biologics market.
The acquisition also adds assets for respiratory inflammation, including APG273 (an IL-13/TSLP combination) and APG333 (anti-TSLP), which showed prolonged biomarker suppression in early data, supporting infrequent dosing strategies in asthma.
Beyond the Apogee assets, AbbVie continues expanding its established franchises. New Phase 3 data for subcutaneous Skyrizi induction in Crohn’s disease demonstrated strong clinical and endoscopic outcomes, including higher rates of endoscopic remission. Rinvoq is advancing in multiple indications, including vitiligo, alopecia areata, hidradenitis suppurativa, and systemic lupus erythematosus. Additional early- and mid-stage programs targeting novel pathways (such as combinations with Skyrizi and assets like lutikizumab) aim to further elevate standards of care in inflammatory bowel disease, psoriasis, rheumatoid arthritis, and other immune-mediated conditions.
Oncology Momentum with Next-Generation ADCs and T-Cell Engagers
AbbVie’s oncology pipeline has gained significant traction. Telisotuzumab adizutecan (Temab-A or ABBV-400), a next-generation c-Met-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, recently received two FDA Breakthrough Therapy Designations—one in combination with bevacizumab for refractory metastatic colorectal cancer and another as monotherapy for previously treated c-Met-expressing, EGFR wild-type nonsquamous non-small cell lung cancer. These designations, based on promising early data from the first-in-human study, highlight the potential of c-Met as a therapeutic target across solid tumors and expand AbbVie’s growing ADC portfolio.
In hematologic malignancies, etentamig (ABBV-383), a BCMA × CD3 bispecific T-cell engager, delivered positive topline Phase 3 results from the CERVINO trial in triple-class-exposed relapsed/refractory multiple myeloma. It achieved a 74% objective response rate versus 45.7% with standard therapies and reduced the risk of progression or death by 60% (HR 0.40). The convenient monthly dosing schedule after a single step-up dose and manageable safety profile (predominantly low-grade cytokine release syndrome) support its potential for broader outpatient use. Regulatory submissions are anticipated.
Other notable assets include expansions of Epkinly (epcoritamab), Elahere (mirvetuximab soravtansine), and multiple earlier-stage ADCs and multi-specifics targeting solid tumors and hematologic cancers.
Neuroscience Leadership and Additional Growth Drivers
AbbVie has established itself as a leader in neuroscience. Vyalev has exceeded expectations and is on track for blockbuster status. Tavapadon, a D1/D5 partial agonist for Parkinson’s disease, is advancing toward potential approval. The migraine portfolio continues to expand with atogepant (Qulipta) and ubrogepant (Ubrelvy), including programs in menstrual migraine. Promising mid-stage assets in psychiatry, such as emraclidine (M4 PAM) for schizophrenia and psychosis, and bretisilocin for major depressive disorder, add further depth.
In eye care, the gene therapy ABBV-RGX-314 (in collaboration with REGENXBIO) is progressing in Phase 3 for wet age-related macular degeneration and diabetic retinopathy, offering the potential for one-time treatment. An early-stage obesity candidate, ABBV-295 (a long-acting amylin analog), has shown favorable Phase 1 data on tolerability and pharmacokinetics, representing a targeted investment in a high-growth metabolic area.
Looking Ahead
AbbVie’s pipeline strategy balances the advancement of near-term catalysts—such as Skyrizi subcutaneous induction in Crohn’s disease, Rinvoq label expansions, etentamig submission, and Temab-A progression—with longer-term innovation through internal discovery, partnerships (including AI-enabled efforts), and bolt-on acquisitions. Anticipated key events through 2026 and 2027 include multiple regulatory approvals, Phase 3 readouts, and early data that could further de-risk the portfolio.
By combining commercial execution on current growth platforms with a robust late-stage and earlier pipeline, AbbVie is well-positioned to deliver sustained innovation for patients and long-term value for stakeholders. The company’s focused approach across immunology, oncology, and neuroscience underscores a clear path beyond the Humira era toward diversified, durable growth.
Disclaimer:
The information provided through this channel does not constitute financial advice and should not be construed as such. This content is for purely informational and educational purposes. Financial decisions should be based on a careful evaluation of your own circumstances and consultation with qualified financial professionals. The accuracy, completeness or timeliness of the information provided is not guaranteed, and any reliance on it is at your own risk. Additionally, financial markets are inherently volatile and can change rapidly. It is recommended that you conduct thorough research and seek professional advice before making significant financial decisions. We are not responsible for any loss, damage or consequences that may arise directly or indirectly from the use of this information.